Literature DB >> 34105263

Chinese expert consensus on gastroesophageal reflux disease in 2020.

Ying Lian Xiao1, Li Ya Zhou2, Xiao Hua Hou3, Yan Qing Li4, Duo Wu Zou5, Min Hu Chen1.   

Abstract

Entities:  

Year:  2021        PMID： 34105263     DOI： 10.1111/1751-2980.13028

Source DB:  PubMed          Journal:  J Dig Dis        ISSN： 1751-2972            Impact factor:   2.325


× No keyword cloud information.
  5 in total

1.  Cost-Utility Analysis of CYP2C19 Genotype Detection for Selection of Acid-Suppressive Therapy with Lansoprazole or Vonoprazan for Patients with Reflux Esophagitis in China.

Authors:  Zhuolin Zhang; Yuwen Bao; Lele Cai; Yajie Gu; Ting Yang; Xin Li
Journal:  Clin Drug Investig       Date:  2022-08-22       Impact factor: 3.580

2.  Validity of a Soft and Flexible 3D-Printed Nissen Fundoplication Model in Surgical Training.

Authors:  Yangyi Zhang; Jianfu Xia; Jiye Zhang; Jinlei Mao; Hao Chen; Hui Lin; Pan Jiang; Xinzhong He; Xiaodong Xu; Mingzhu Yin; Zhifei Wang
Journal:  Int J Bioprint       Date:  2022-03-23

3.  Cost-effectiveness analysis of vonoprazan versus proton pump inhibitors in the treatment of reflux esophagitis in China.

Authors:  Zhenhua Wang; Ruixiaotong Sun; Yanan Sheng; Shuli Qu; Lu Dong; Bin Wu
Journal:  Ann Transl Med       Date:  2022-04

Review 4.  The role of vonoprazan in patients with erosive esophagitis.

Authors:  Mengyu Zhang; Yinglian Xiao; Minhu Chen
Journal:  Therap Adv Gastroenterol       Date:  2022-09-13       Impact factor: 4.802

5.  Clinical outcomes of asymptomatic low-grade esophagitis: results from a multicenter Chinese cohort.

Authors:  Songfeng Chen; Xuelian Xiang; Xiaohao Zhang; Qianjun Zhuang; Niandi Tan; Xun Hou; Mengyu Zhang; Junnan Hu; Chaofan Duan; Yi Cui; Jinhui Wang; Xiangbin Xing; Nina Zhang; Yinglian Xiao
Journal:  Gastroenterol Rep (Oxf)       Date:  2022-10-13
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.